Serotonergic function and negative and depressive symptomatology in schizophrenia and major depression

[1]  R. Murray,et al.  Reduced Prolactin and Cortisol Responses to d-Fenfluramine in Depressed Compared to Healthy Matched Control Subjects , 1996, Neuropsychopharmacology.

[2]  V. O’Keane,et al.  Enhancement of the Prolactin Response to d-Fenfluramine in Drug-Naive Schizophrenic Patients , 1996, British Journal of Psychiatry.

[3]  H. Meltzer,et al.  Effect of pindolol pretreatment on MK-212-induced plasma cortisol and prolactin responses in normal men , 1995, Biological Psychiatry.

[4]  W. Carpenter.  Serotonin‐Dopamine Antagonists and Treatment of Negative Symptoms , 1995, Journal of clinical psychopharmacology.

[5]  F. Bloom,et al.  Psychopharmacology: The Fourth Generation of Progress , 1995 .

[6]  J. McEvoy,et al.  Pharmacotherapy of impaired affect in recovering schizophrenic patients. , 1995, Archives of general psychiatry.

[7]  J. Macher,et al.  Endocrine responses to D,L- and D-fenfluramine in psychiatry , 1994, Biological Psychiatry.

[8]  A. Caputi,et al.  Adjunctive fluoxetine in the treatment of negative symptoms in chronic schizophrenic patients , 1994, International clinical psychopharmacology.

[9]  P. Botter,et al.  Ritanserin, a Selective 5-HT2/1C Antagonist, and Negative Symptoms in Schizophrenia , 1993, British Journal of Psychiatry.

[10]  S. Woods,et al.  m-Chlorophenylpiperazine effects in neuroleptic-free schizophrenic patients. Evidence implicating serotonergic systems in the positive symptoms of schizophrenia. , 1993, Archives of general psychiatry.

[11]  T. Dinan,et al.  D-fenfluramine-induced prolactin and cortisol release in major depression: response to treatment. , 1992, Journal of affective disorders.

[12]  W. Maier,et al.  Risperidone in the Treatment of Disorders with a combined Psychotic and Depressive Syndrome - A Functional Approach , 1992, Pharmacopsychiatry.

[13]  H. Meltzer.  Treatment of the neuroleptic-nonresponsive schizophrenic patient. , 1992, Schizophrenia bulletin.

[14]  R. Kahn,et al.  The MCPP challenge test in schizophrenia: Hormonal and behavioral responses , 1991, Biological Psychiatry.

[15]  H. Silver,et al.  Treatment of chronic schizophrenia with cyproheptadine: A double-blind placebo-controlled study , 1991, Biological Psychiatry.

[16]  T. Dinan,et al.  Prolactin and cortisol responses to d-fenfluramine in major depression: evidence for diminished responsivity of central serotonergic function. , 1991, The American journal of psychiatry.

[17]  T. Dinan,et al.  d‐Fenfluramine/prolactin response throughout the menstrual cycle: evidence for an oestrogen‐induced alteration , 1991, Clinical endocrinology.

[18]  J. Mann,et al.  Effects of age and gender on CNS serotonergic responsivity in normal adults , 1990, Biological Psychiatry.

[19]  S. Svebak,et al.  Clonazepam and imipramine in the treatment of panic attacks: a double-blind comparison of efficacy and side effects. , 1990, The Journal of clinical psychiatry.

[20]  B. Bunney,et al.  Acute Effects of Typical and Atypical Antipsychotic Drugs on the Release of Dopamine from Prefrontal Cortex, Nucleus Accumbens, and Striatum of the Rat: An In Vivo Microdialysis Study , 1990, Journal of neurochemistry.

[21]  C. de Montigny,et al.  A role for the serotonin system in the mechanism of action of antidepressant treatments: preclinical evidence. , 1990, The Journal of clinical psychiatry.

[22]  K. Lesch,et al.  Corticotropin and cortisol secretion after central 5-hydroxytryptamine-1A (5-HT1A) receptor activation: effects of 5-HT receptor and beta-adrenoceptor antagonists. , 1990, The Journal of clinical endocrinology and metabolism.

[23]  H. Silver,et al.  Neuroendocrine responses in chronic schizophrenia Evidence for serotonergic dysfunction , 1988, Schizophrenia Research.

[24]  R. Kahn,et al.  The role of serotonin in schizophrenia. , 1988, Schizophrenia bulletin.

[25]  P. Cowen,et al.  Endocrine responses to tryptophan infusion in schizophrenic patients treated with neuroleptics , 1987, Psychoneuroendocrinology.

[26]  S. Garattini,et al.  From Fenfluramine Racemate to d‐Fenfluramine , 1987 .

[27]  R. Kahn,et al.  Hormonal probes of central serotonergic activity: Do they really exist? , 1987, Biological Psychiatry.

[28]  H. Meltzer,et al.  Psychopharmacology : the third generation of progress , 1987 .

[29]  R. Manna,et al.  Effect of fenfluramine on growth hormone and prolactin secretion in obese subjects. , 1987, Hormone research.

[30]  A. Holt.  Controversies in schizophrenia , 1986 .

[31]  André Reyntjens,et al.  Thymosthenic effects of ritanserin (R 55667), a centrally acting serotonin‐S2 receptor blocker , 1986 .

[32]  S. Garattini,et al.  d- and l-isomers of fenfluramine differ markedly in their interaction with brain serotonin and catecholamines in the rat. , 1986, European journal of pharmacology.

[33]  Y. Hoshino,et al.  Endocrinological Function in Schizophrenic Patients under Haloperidol Treatment: Plasma PRL, HGH and 5HT Levels after L‐5HTP Loading , 1985, Folia psychiatrica et neurologica japonica.

[34]  R. Knight,et al.  Affectivity in schizophrenia. , 1985 .

[35]  M. Hamilton.  A RATING SCALE FOR DEPRESSION , 1960, Journal of neurology, neurosurgery, and psychiatry.